Phillips O A, Czajkowski D P, Spevak P, Singh M P, Hanehara-Kunugita C, Hyodo A, Micetich R G, Maiti S N
SynPhar Laboratories Inc., Taiho Alberta Center, Canada.
J Antibiot (Tokyo). 1997 Apr;50(4):350-6. doi: 10.7164/antibiotics.50.350.
A new beta-lactamase inhibitor, SYN-1012, with a penem skeleton was synthesized and its biological activity compared with clavulanic acid, sulbactam, tazobactam and BRL-42715. The beta-lactamase inhibitory activity of SYN-1012 was comparable to BRL-42715. Clavulanate and penam sulphones (sulbactam and tazobactam) were more active against TEM-1 and OXA-1, but were less active against TEM-3 and cephalosporinase (Case) than SYN-1012. In combination with piperacillin, SYN-1012 exhibited comparable or slightly lower synergistic effects than BRL-42715 against all the Gram-positive and Gram-negative isolates tested with only exception of Pseudomonas aeruginosa. The separate combinations of SYN-1012 and BRL-42715 with ceftazidime and cefotaxime provided comparable results against Gram-negatives, but not against Gram-positive isolates. Tazobactam was inferior to SYN-1012 in all cases. In comparison to tazobactam, SYN-1012 and BRL-42715 were relatively unstable in human and mouse plasma, and in mouse liver and kidney homogenates. Serum level of SYN-1012 and BRL-42715 after an intravenous administration of 20 mg/kg in rabbit was undetectable after 1 hour.
合成了一种具有青霉烯骨架的新型β-内酰胺酶抑制剂SYN-1012,并将其生物活性与克拉维酸、舒巴坦、他唑巴坦和BRL-42715进行了比较。SYN-1012的β-内酰胺酶抑制活性与BRL-42715相当。棒酸和青霉烷砜(舒巴坦和他唑巴坦)对TEM-1和OXA-1的活性更高,但对TEM-3和头孢菌素酶(Case)的活性低于SYN-1012。与哌拉西林联合使用时,SYN-1012对所有测试的革兰氏阳性和革兰氏阴性分离株(仅铜绿假单胞菌除外)表现出与BRL-42715相当或略低的协同作用。SYN-1012和BRL-42715与头孢他啶和头孢噻肟的单独联合使用对革兰氏阴性菌的结果相当,但对革兰氏阳性分离株无效。在所有情况下,他唑巴坦均不如SYN-1012。与他唑巴坦相比,SYN-1012和BRL-42715在人及小鼠血浆以及小鼠肝和肾匀浆中相对不稳定。在兔静脉注射20mg/kg后1小时,未检测到SYN-1012和BRL-42715的血清水平。